Abstract 296P
Background
Unresectable malignant biliary obstruction confers a poor prognosis. Drainage of the biliary system with percutaneous trans-hepatic biliary drainage (PTBD) is offered with the intent of palliation of symptoms or to enable SACT (systemic anti-cancer treatment) but is associated with significant morbidity and mortality. Repeat PTBD for oncology patients was reviewed, asessing factors associated with poor outcomes to improve patient selection for PTBD.
Methods
Retrospective study of patients undergoing repeat PTBD at University Hospital Coventry & Warwickshire between 2015-2020. By collating data from the hospital database, morbidity and mortality of a repeat PTBD was reviewed, and factors associated with increased mortality noted.
Results
27 cases of repeat PTBD for recurrent malignant biliary obstruction were identified and analysed out of a total of 211 PTBD procedures performed for malignant biliary obstruction. Median survival was 81 days (range 22-455), median length of stay 15 days (range 2-52), and median age 66 (range 34-81). Mortality: in hospital was 3.7%, 7 day 0%, 30 day 7.4% and 90 day 48%. Factors associated with lower median survival rates were: male gender, age > 65, receiving SACT (either before or after PTBD), complications of post procedure sepsis and a pre-procedure bilirubin of greater than 100 umols/L. Patients receiving SACT within 3 months prior to PTBD had better median survival compared to those who had SACT > 3 months prior (90 days vs 72). SACT following PTBD had the highest median survival (278 days). Comparatively, cases receiving no chemotherapy (pre or post PTBD) had the lowest median survival (69 days) Table: 296P
Median survival following PTBD (days)
Female | Male |
110 | 68 |
Age <65 | Age 65+ |
96 | 81 |
SACT | No SACT |
91 | 69 |
No sepsis | Sepsis |
103 | 75 |
Bilirubin <100umol/L | Bilirubin >100umol/L |
96 | 83 |
Post procedure sepsis reduced median survival and increased median length of stay from 10 to 17 days.
Conclusions
Repeat PTBD in this cohort of patients showed a similar median survival to those undergoing first episode of PTBD (81 vs 88 days respectively). Features associated with better outcomes that could potentially guide patient selection include: lower age, female gender, lower bilirubin pre-procedure and being on active SACT or progressing to SACT post procedure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session